Medicus Pharma Ltd. MDCX PHARMA
Company Overview
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -91.90% |
| 6 Months: | -67.31% |
| 3 Months: | -49.40% |
| 1 Month: | -43.33% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)27.42 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 93.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MDCX Medicus Pharma Ltd. PHARMA | 0.17 | -0.07 | $12.19M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Income | -1.71M | -3.55M | -2.33M | -5.13M | -6.02M | -15 | -8.60M |
| Net Income | -1.71M | - | -2.28M | -5.10M | - | -20.94M | -9.04M |
| Diluted EPS | -0.21 | -0.44 | -0.24 | -0.42 | -0.43 | -1.12 | -0.31 |
| R&D Expense | 321.38K | 1.28M | 564.14K | 2.01M | 1.44M | 1.68M | 2.70M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Income | -4.73M | -11.18M | -34.36M |
| Net Income | -5.31M | -11.16M | -47.28M |
| Diluted EPS | -1.53 | -1.16 | -2.74 |
| R&D Expense | 193.58K | 3.53M | 7.72M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 282.65K | 1.89M | 5.65M | 10.06M |
| Current Assets | - | 282.65K | 1.89M | 5.38M | 9.89M |
| Cash & Equivalents | - | 267.65K | 1.72M | 4.16M | 8.71M |
| Inventory | - | - | - | - | - |
| Receivables | - | - | - | - | - |
| Total Liabilities | - | 12.48M | 781.61K | 2.51M | 10.02M |
| Current Liabilities | - | 12.48M | 781.61K | 2.31M | 9.94M |
| Long Term Debt | - | - | - | - | 25.86K |
| Total Debt | - | 1.53M | 0 | 322.27K | 5.48M |
| Total Equity | - | -12.20M | 1.11M | 3.13M | -67.55K |
| Shares Outstanding | - | 8.05M | 8.08M | 11.82M | 25.18M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -4.16M | -10.25M | -22.78M |
| Investing Cash Flow | - | 0 | -4.62M |
| Financing Cash Flow | 5.61M | 12.69M | 31.94M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | -478.2% | -355.9% | 69,990.7% |
| ROCE % | -425.6% | -334.7% | -27,863.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Interchange Capital Partners, LLC | 2.51% | 1.59M | $270.24K |
| 2 | Jane Street Group, LLC | 0.53% | 333.67K | $56.82K |
| 3 | Xtx Topco Ltd | 0.39% | 243.36K | $41.44K |
| 4 | Sterling Investment Advisors, Ltd. | 0.16% | 100.00K | $17.03K |
| 5 | Commonwealth Equity Services, LLC | 0.08% | 52.64K | $8.96K |
| 6 | May Hill Capital, LLC | 0.08% | 50.62K | $8.62K |
| 7 | Stifel Financial Corporation | 0.05% | 30.00K | $5.11K |
| 8 | Susquehanna International Group, LLP | 0.05% | 31.46K | $5.36K |
| 9 | Wilmington Savings Fund Society, FSB | 0.04% | 25.62K | $4.36K |
| 10 | JPMORGAN CHASE & CO | 0.04% | 25.62K | $4.36K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MDCX
CFO adds Medicus Pharma (MDCX) stock and options - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPSmVRQkhEQmp2VG1EaW95THE3X1llNEdWNkUwaklwMlBnWFlhclVBRHpaV1FhNWhPblpFZFZWakQ1SlBfTXhtOGVheEZNZUV1ZHFOV2JycGM5SDg2NXRiT2kyeW9SQjUwY1NjM1Y4SlBmdHlWaDY2M1FkWDFTMW45cVV4UjBjU0R5TTFRcl…
MDCX Stock Price, Quote & Chart - ChartMill
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBCaTVPdlN3OXJiY0R5M3FVM1hfVmp3YUhfNFYySm1hYWw4MDJubDd6SmNKUzAwTWhmYkRzTm9rLUc0SFc4LVlDdjdCTzVHWktVTGVCdDBjNVA1WXk0TEtF?oc=5" target="_blank">MDCX Stock Price, Quote & Chart</a>&nbs…
Medicus Pharma (MDCX) grants COO 735K shares and options - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQb0pzSGtoVEtMNWVmTGxsOW1nanFXVkptbHk3MGZGRzhXaUVrbk1scmQ4UHNveldoclJHUlVpODY2Wkc5MW01b0F0QmlPWWpnLUdoc3BIdktRLVJSalZESGwxX1pMVmZtUmh1Snl3M20zVTlSUjMzYU5nRWw2V1lYcXhGejJKQXJhVXNwMU…
Is Medicus Pharma Ltd. (MDCX) Stock Gaining Momentum With Innovative Skin Cancer Treatment Technology? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxNTHh3T2hxWWVrcmEwd0xBS1QyWFBuenJ0aFh0ajh6RVE0WnVQbWFEUU9lbEtoS2lHODVYZEttcmlMM0EzU0N5dEtCMS1EYWNjLUNtUkJ6Nnd6MXNPLVlvNjFKeU9DcDRWRHI0N09OMU5sUVg0ME1Wd1B4MVVSSVFnUGlJRVo4VTc0d0FaNz…
MDCX Should I Buy - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE14d2pNeWxNLUdnWklVUDBaR1F1MTc4T2NlaGo1VHhxM3VILV9Wbk8tVTVJTjRtOTFiajBZVWh1eTlMVlFUQmdZOExUVTNDTUJpWFNYb0ZuRFZuVUloZGc?oc=5" target="_blank">MDCX Should I Buy</a> <font c…
Medicus Pharma (MDCX) 10K Form and Latest SEC Filings 2026 - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTFB6SG9NMjJOaG5pcFpOM2xHdndkQmx3Nmh4Rk5rWnZZSHBnbFpJUzNJOHdteG4zamd6b2ZBd0YwUWR6Yy0xLWdsSzBiZmhHdkplMHQtYkZQRVBnX0Nmd1haWU9LQzE1b2g1cEE?oc=5" target="_blank">Medicus Pharma (MDCX) 10…
MDCX — Frequently Asked Questions
What is the current share price of Medicus Pharma Ltd. (MDCX)?
As of 2026-09-19 21:16 PDT, Medicus Pharma Ltd. (MDCX) trades at $0.17 on NasdaqCM. Its 52-week range is $0.17 to $2.80.
What is the market capitalisation of MDCX?
Medicus Pharma Ltd. (MDCX) has a market capitalisation of $12.19M on NasdaqCM.
What is the P/E ratio of MDCX?
MDCX trades at a trailing price-to-earnings (P/E) ratio of -0.07. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.16.
Is MDCX a good stock to buy?
This page provides a data-driven analysis of Medicus Pharma Ltd. (MDCX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.